At Biocon, were working across the healthcare ecosystem to advance biosimilar adoption, partnering with policymakers, regulators and industry groups to help expand access and improve affordability for patients
In June 2021, the US Food and Drug Administration (FDA) approved semaglutide for chronic weight management in adults with a body mass index (BMI) of 277 or greater who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
The role of enterovirus in chronic fatigue syndrome
Alcohol can worsen Ozempic side effects like nausea and may affect blood sugar levels
The best weight loss clinic considers your current fitness level when suggesting movement strategies that enhance best over the counter weight loss pills results
Rajguru to assess how your hormone levels are affected